Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$4.04 - $5.47 $50,500 - $68,375
12,500 New
12,500 $53,000
Q1 2022

May 13, 2022

SELL
$8.42 - $15.32 $349,320 - $635,580
-41,487 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $605,295 - $964,987
41,487 New
41,487 $626,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.